Biohaven and Yale University secured a $4 million jury verdict against Avilar Therapeutics and RA Capital for willful and malicious trade secret misappropriation and breach of contract. This outcome validates Biohaven's licensing of Yale's MODA platform and provides a financial award, though the overall market impact for Biohaven is likely moderate given the relatively small damages awarded compared to its market capitalization.
A federal jury found Avilar Therapeutics and RA Capital liable for willfully and maliciously misappropriating a Yale trade secret (the MODA platform) and for RA Capital breaching a confidentiality agreement. Biohaven, which licensed the MODA platform from Yale, was a co-plaintiff and will receive $1 million of the $4 million awarded in damages. This verdict is a positive development for Biohaven, validating its intellectual property and partnership with Yale, and potentially deterring future IP infringement. For Avilar and RA Capital, it's a negative outcome, resulting in financial penalties and reputational damage. While the $4 million award is not a massive sum for a company like Biohaven, it reinforces the value of its licensed technology. Short-term, this could provide a minor sentiment boost for BHVN. Long-term, it underscores the importance of IP protection in the biotech sector and could influence how investment firms engage with early-stage technologies.